RecruitingRecruiting
A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease
NCT07908381 · Enanta Pharmaceuticals, Inc
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Randomized, Double-blind, Placebo-controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Zelicapavir for Respiratory Syncytial Virus Infection in Adults Who Are at High Risk for Severe Disease
About this study
Zelicapavir is a novel orally administered non-fusion replication inhibitor of RSV that is being developed for the treatment of patients with RSV infection. This phase 2b/3 study will evaluate the efficacy and safety of zelicapavir compared with placebo in adults with RSV who are at high risk for severe disease. High-risk participants include those who are either ≥75 years of age or ≥18 years of age with COPD and/or CHF. Participants will be non-hospitalized adults who have up to 72 hours of respiratory tract infection symptoms and test positive for RSV.
Eligibility criteria
Inclusion Criteria:
* Age ≥75 years at the time of enrollment, or, age ≥18 at the time of enrollment and has at least one of the following conditions that predispose them to complications of RSV infection:
1. CHF
2. COPD
* New onset or worsening of preexisting symptoms consistent with respiratory tract infection no more than 72 hours before administration of the first dose of study intervention: feeling feverish, headache, neck pain, fatigue, loss of appetite, interrupted sleep, body aches, sore throat, nasal congestion, cough, cough with phlegm, wheezing, or short of breath.
* Reports at least 2 of the following symptoms, one of which must be reported by the participant as at least moderate in severity using the RiiQ™: cough, cough with phlegm, wheezing, or short of breath.
* Tested positive for RSV infection defined as a positive nucleic acid amplification test (PCR or other) or rapid-antigen viral detection test performed on a nasal swab specimen collected no more than 72 hours before administration of the first dose of study intervention.
* A woman of childbearing potential who is sexually active with a male must agree to use two effective methods of contraception from the date of Screening until 30 days after her last dose of study drug.
* A male subject who has not had a vasectomy and is sexually active with a woman of childbearing potential must agree to use effective contraception from the date of Screening to 90 days after his last dose of study drug.
Exclusion Criteria:
* Reported history of respiratory infection (other than RSV) within 7 days prior to signing the ICF.
* Anticipated need for hospitalization within 24 hours of signing the ICF.
* Receiving dialysis or have known severe renal impairment.
* Reported history of chronic liver disease, including cirrhosis, autoimmune hepatitis, end stage liver disease, history of hepatocellular carcinoma, or decompensated liver failure.
* Prior receipt of or waiting to receive a bone marrow, stem cell, or solid organ transplant. Currently taking, or has taken within 7 days prior to randomization, or is anticipated to receive during the study, systemic medications that are known to cause immunosuppression. Note: Chronic use of immunomodulators such as dupilumab and omalizumab is permitted.
Study design
Enrollment target: 860 participants
Allocation: randomized
Masking: triple
Age groups: adult, older_adult
Timeline
Starts: 2026-10-19
Estimated completion: 2029-07
Last updated: 2026-11-02
Interventions
Drug: zelicapavirDrug: Placebo
Primary outcomes
- • Time to complete resolution of all 13 RSV symptoms as assessed by the Respiratory Infection Intensity and Impact Questionnaire (RiiQ) symptom scale (Day 1 through Day 21)
Sponsor
Enanta Pharmaceuticals, Inc · industry
Contacts & investigators
ContactChris Harris, MD · contact · charris@enanta.com · 617-607-0800
InvestigatorEnanta Pharmaceuticals, Inc · study_director, Enanta Pharmaceuticals, Inc
All locations (4)
C&A Clinical Trials CorpRecruiting
Cape Coral, Florida, United States
Continental Clinical Research, LLCRecruiting
Miami, Florida, United States
PanAmerican Clinical ResearchRecruiting
Bluffton, South Carolina, United States
PanAmerican Clinical Research - BrownvilleRecruiting
Brownsville, Texas, United States